drugset / Trial / NCT00683735

Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis

NCT00683735

Phase 2/3 Completed 20 enrolled Michael A. Nauck
RandomizedCrossoverDouble-blindTreatment

Summary

Objective: To assess the effect if co-administration of sitagliptin and metformin compared to placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic' intravenous glucose load). Hypothesis: Treatment with co-administration of sitagliptin and metformin provides a greater incretin effect compared to placebo.

Timeline

Start
2009-02
Primary completion
2012-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 2000 mg
Comparator Sitagliptin Small molecule 100 mg